FCRL5
FCRL5全稱為Fc受體樣蛋白5，也被稱為FcRH5或CD307，是一種主要表達于B細胞表面的跨膜蛋白。它與免疫球蛋白Fc段結構類似，但功能不同于傳統Fc受體，在B細胞發育和活化中具有獨特調節作用。FCRL5通過胞內ITAM結構域參與調控B細胞受體信號，其異常表達可能打破免疫耐受，與類風濕性關節炎、系統性紅斑狼瘡等自身免疫病密切相關。近年來在腫瘤領域中發現，FCRL5在多發性骨髓瘤、彌漫大B細胞淋巴瘤等B細胞惡性腫瘤中特異性高表達，已成為新型治療靶點。
針對FCRL5的藥物研發主要聚焦雙特異性抗體和CAR-T療法。2021年進入臨床試驗的Cevostamab是全球首個靶向FCRL5的雙抗藥物，通過同時結合CD3和FCRL5激活T細胞殺傷腫瘤，在復發/難治性多發性骨髓瘤中已顯示出客觀緩解。利用FCRL5作為CAR-T靶點的臨床前研究也取得突破，其特異性表達特點可減少對正常B細胞的影響。目前該靶點相關研究已獲得FDA孤兒藥資格認定，未來可能為B細胞相關疾病提供更精準的治療選擇。
熱銷產品
Recombinant Human Fc receptor-like protein 5 (FCRL5), partial (CSB-MP853494HU)
驗證數據
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
驗證數據
Western blot analysis of extracts from Jurkat cells, using FCRL5 antibody.
FCRL5 Antibodies
FCRL5 for Homo sapiens (Human)
| 產品貨號 | 產品名稱 | 種屬反應性 | 應用類型 |
|---|---|---|---|
| CSB-PA791000 | FCRL5 Antibody | Human | ELISA,WB |
| CSB-PA005263 | FCRL5 Antibody | Human | WB, ELISA |
| CSB-PA060251 | FCRL5 Antibody | Human | WB, ELISA |
| CSB-PA853494LA01HU | FCRL5 Antibody | Human | ELISA, IF |
| CSB-PA853494LB01HU | FCRL5 Antibody, HRP conjugated | Human | ELISA |
| CSB-PA853494LC01HU | FCRL5 Antibody, FITC conjugated | Human | |
| CSB-PA853494LD01HU | FCRL5 Antibody, Biotin conjugated | Human | ELISA |
FCRL5 Proteins
FCRL5 Proteins for Mus musculus (Mouse)
| 產品貨號 | 產品名稱 | 來源 |
|---|---|---|
| CSB-YP718110MO CSB-EP718110MO CSB-BP718110MO CSB-MP718110MO CSB-EP718110MO-B |
Recombinant Mouse Fc receptor-like protein 5 (Fcrl5), partial | Yeast E.coli Baculovirus Mammalian cell In Vivo Biotinylation in E.coli |
FCRL5 Proteins for Homo sapiens (Human)
| 產品貨號 | 產品名稱 | 來源 |
|---|---|---|
| CSB-YP853494HU CSB-EP853494HU CSB-BP853494HU CSB-EP853494HU-B |
Recombinant Human Fc receptor-like protein 5 (FCRL5), partial | Yeast E.coli Baculovirus In Vivo Biotinylation in E.coli |
| CSB-MP853494HU | Recombinant Human Fc receptor-like protein 5 (FCRL5), partial | Mammalian cell |
